NCT04730856

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 311 (actual)
• Sponsor: Hospital Universitario Infanta Leonor · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective is to evaluate the efficacy and safety of three doses of tinzaparin (prophylactic, intermediate and therapeutic) in hospitalized patients with COVID-19 pneumonia.

Conditions

• Covid19
• Thrombosis

Interventions

Type	Name	Description
DRUG	Tinzaparin	day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home. • Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home.

Timeline

• Start date: 2021-02-01
• Primary completion: 2021-10-20
• Completion: 2021-12-20
• First posted: 2021-01-29
• Last updated: 2022-09-15

Locations

18 sites across 1 country: Spain